BCL2 and Thrombocytopenia: Navitoclax has reached clinical trials for several types of cancer [7]; however, its inhibition of other members of the family, such as BCL-XL, produces thrombocytopenia, which impedes its clinical translation for age-related diseases; therefore, new strategies to overcome the on-target toxicity of navitoclax and to advance the BCL-2 inhibitors to clinical translation are under study.